30 closest matches · ranked by relevance
Metabolic Syndrome · Diabetes Mellitus, Type 2 · Pre Diabetes
Primary: Hemoglobin A1c — -.42; -0.37; 0.02 % of hemoglobin — p=0.001
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Healthy
Primary: Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet — 0.672; 4.83 µmol/100g/min
Healthy Adults
Primary: Plasma Acetoacetate Concentrations — 26.06; 30.99; 32.10 µmol/L
Cystic Fibrosis
Primary: Pulmonary Function Testing — 1.9; 2.0 L/sec
Ketosis · Blood Glucose
Primary: Blood Beta-hydroxybutyrate — 217; 192; 176 area under the curve (mmol/L x 240 min)
Prediabetic State
Primary: Plasma Ketone Concentrations — -52; 12; 493; 627 (µmol/h)/L
Heart Failure · Type 2 Diabetes Mellitus
Primary: Cardiac Output (CO) — 5.02; 4.54; 5.93; 5.10 mL/min
Ketosis · Type 2 Diabetes
Primary: Plasma Glucose — 7.3; 7.2; 6.2; 6.6 mmol/L
Healthy Adults
Primary: Concentration of Total Plasma Ketones — -18.2; 23; 12.2; 68.5 µmol/L
Ketosis
Primary: Change in Venous Plasma Beta-hydroxybutyrate (BHB) From Baseline to Peak During Acute Ketosis Exposure — 3.5; 0.04 mmol/l
Polycystic Ovary Syndrome
Primary: Mean Percent Body Weight Loss — -7.67 percentage of weight — p=<.001
Diabetes Mellitus, Type 1
Primary: Capillary Blood Beta-hydroxybutyrate (BOHB) During Outpatient Care — 0.1; 0.2 mmol/L — p=< 0.0001
Healthy
Primary: Plasma Ketone Concentration — 136.97; 177.43; 270.61; 249.3 µmol/L
Glioblastoma
Primary: Number of Participants With Ketosis — 9 Participants
Diabetes Mellitus · Obesity
Primary: Change From Baseline in Body Weight at 48 Weeks — -9.5; -8.5 percentage of weight loss
Heart Failure With Preserved Ejection Fraction
Primary: Maximal Exercise Capacity (Peak VO2) Assessed by Cardiopulmonary Exercise Testing — 1.0; 1.0 L/min
Heart Failure With Reduced Ejection Fraction
Primary: Venous pH Measured Via Peripheral Blood — 7.30; 7.28 unitless
Evaluate Ketogenic Stress
Primary: Change in Beta-hydroxybutyrate Levels in Blood — -0.23; 0.63; 0.24; 0.31 mM
Alcoholism
Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067
Type 1 Diabetes
Primary: Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin — 0.08; 0.25; 0.21 mM
Cancer
Primary: To Determine the Safety and Tolerability of a Modified Low Carbohydrate Diet in People With Advanced Cancer Across Different Tumor Types. — 11 participants
Dehydration
Primary: Measurement of Serum Ketones Before and After Administration of Intravenous Fluids for Acute Gastroenteritis — 1.10; 2.39 mmol/L — p=0.0003
Type1diabetes, Low Carbohydrate Diet
Primary: Percent Time in the Optimal Glucose Range — 71.20; 62.51 percentage of time — p=<0.001
Empaglifozin · Physiological Effects of Drugs · Hypoglycemic Agents
Primary: Change in Serum β-hydroxybutyrate (BHB) — 40.717 µM — p=<0.001
Healthy Adults
Primary: Plasma Ketone Concentrations — 69; 294; 109; 363 µmol/L
Ketosis Prone Diabetes · Diabetes Ketoacidosis · Hyperglycemia
Primary: Length of Remission — 472; 589; 111 days
Healthy
Primary: Ketone Production — 217.71; 187.48 µmol/L
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Carnitine Palmitoyltransferase 2 Deficiency
Primary: Energy Expenditure — 2045; 2343 kcal
Recurrent Glioblastoma
Primary: Progression-free-survival — 20; 16 percentage of participants